Patents Examined by Natalie Moss
  • Patent number: 9839656
    Abstract: A composition comprising specific Lactobacillus helveticus strains is provided for reducing the symptoms of allergies originating from food, respiratory or contact allergens. Preferably the composition reduces symptoms of allergies (secondary prevention) while also able to reduce sensitization (primary prevention).
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: December 12, 2017
    Assignee: Nestec S.A.
    Inventors: Sebastien Holvoet, Annick Mercenier, Marietta Weiss, Adrian Walter Zuercher
  • Patent number: 9828612
    Abstract: A method is provided for the production of alcohol from trees, the method comprising a step of treating a subject tree with mother cell lyases formed through cytolysis associated with sporulation of spore-forming aerobic bacteria, thereby degrading said tree into a powdery state and obtaining a tree degradation product; a step of sterilizing said tree degradation product; a step of treating said sterilized tree degradation product with a koji fungus (Aspergillus oryzae) thereby carrying out a primary fermentation; a step of adding a yeast to the fermentation broth obtained by said primary fermentation thereby carrying out a secondary fermentation; and a step of filtering the fermentation broth obtained by said secondary fermentation, wherein said mother cell lyases are obtained by culturing said spore-forming aerobic bacteria, subjecting the resultant culture medium to a starvation state, thereby converting said bacteria into endospores, and removing impurities including said endosporic bacteria from said cul
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: November 28, 2017
    Assignees: Meisho Co., Ltd., Fujisawa Environment Development Co., Ltd.
    Inventors: Kaoru Mitarai, Miho Sakai, Kenji Matsui
  • Patent number: 9827264
    Abstract: A method and system for identifying and treating various medical conditions caused by toxins, pathogens, hormonal imbalances and other factors involving intravenous therapy.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: November 28, 2017
    Inventor: Wyatt J. Palumbo
  • Patent number: 9828580
    Abstract: Methods, systems, devices and materials for producing biofuels under nanoscale control (“nanobiofuels”) are provided. In one aspect, the invention provides method for producing a biofuel, including providing a hydrocarbon producing organism; exposing the biological hydrocarbon producing organism to conditions effective to cause substantial release of the hydrocarbon from the biological hydrocarbon producing organism; and isolating at least a portion of the hydrocarbon. At least one of the actions of providing, exposing, and isolating is performed using a corresponding nanoscale control.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: November 28, 2017
    Assignee: Nanobiosym, Inc.
    Inventor: Anita Goel
  • Patent number: 9782441
    Abstract: Methods are provided for treating, mitigating or protecting from radiation-induced injury using bone marrow stromal cells expanded in culture, adipose-tissue derived non-adherent stromal cells, or the culture supernatant thereof.
    Type: Grant
    Filed: July 10, 2012
    Date of Patent: October 10, 2017
    Assignee: Albert Einstein College of Medicine, Inc.
    Inventors: Chandan Guha, Subhrajit Saha, Alan A. Alfieri, Payel Bhanja
  • Patent number: 9763465
    Abstract: The inventions discloses a composition comprising at least one N-acetyl lactosamine, at least one sialylated oligosaccharide and at least one fucosylated oligosaccharide, for use in preventing acute respiratory infections (ARI) and/or relieving symptoms of said ARI infections. Preferably said composition is a starter infant formula. Said acute respiratory infection is in particular bronchiolitis or otitis.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: September 19, 2017
    Assignee: Nestec S.A.
    Inventor: Norbert Sprenger
  • Patent number: 9610328
    Abstract: An improved device and method for extended repair and regeneration of muscle tissue. An exemplary device comprises (a) a scaffold comprising an ECM component; (b) a combination of growth factors such as VEGF and IGF; and (c) a population of myogenic cells. Implantation of the device leads to muscle regeneration and repair over an extended period of time.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: April 4, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: David J. Mooney, Cristina Borselli, Herman Vandenburgh, Dimitry Shvartsman, Hannah Storrie, Jeff Lichtman
  • Patent number: 9592211
    Abstract: A composition comprising alpha-ketoglutaric acid or a pharmaceutically acceptable salt thereof (AKG), and one or more enzymes selected from a group consisting of a lipase, a protease and an amylase, and medical uses thereof in, neurological and/or neurodegenerative disease, neurological trauma, depression or chronic fatigue syndrome.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: March 14, 2017
    Inventor: Stefan Pierzynowski
  • Patent number: 9593361
    Abstract: An article for detecting Salmonella microorganisms is provided. The article comprises a highly selective nutrient medium and a plurality of indicator systems. A method of using the article to detect Salmonella microorganisms is also provided.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: March 14, 2017
    Assignee: 3M Innovative Properties Company
    Inventors: Patrick A. Mach, Mara S. Reif-Wenner
  • Patent number: 9555082
    Abstract: Disclosed is a composition containing Saccharomyces cerevisiae var boulardii and the enzyme superoxide dismutase.
    Type: Grant
    Filed: August 2, 2012
    Date of Patent: January 31, 2017
    Assignee: Gnosis S.p.A.
    Inventors: Ignazio Castagliuolo, Paola Brun, Immacolata Busiello, Niccolo Miraglia
  • Patent number: 9556467
    Abstract: The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: January 31, 2017
    Assignee: Garnet Bio Therapeutics, Inc.
    Inventors: Vanessa Ragaglia, Vandana Madanlal Sharma
  • Patent number: 9523104
    Abstract: The present invention relates to processes and systems for the production of fermentative products such as ethanol and butanol. The present invention also provides methods for separating feed stream components for improved biomass processing productivity.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: December 20, 2016
    Assignee: Butamax Advanced Biofuels LLC
    Inventors: Benjamin Fuchs, Brian Michael Roesch, Mathias E. Stolarski, James Gregory Wood
  • Patent number: 9506103
    Abstract: The invention relates to a procedure for biphasic preparation of liposomes, in the course of which technically simple and cheap mechanical mixing methods are used to commingle non-polar organic phase containing an individual mixture of natural and synthetic phospholipids and polar aqueous (buffer) phase not miscible with it, resulting in a liposome emulsion of a unique structure. Furthermore, the invention comprises embodiments of the procedure related to the in vitro diagnostic use of liposomes prepared in this way, when protein type active components are anchored to the surface of liposome membranes without application of any detergents and non-protein type active components are simply mixed with the liposome emulsion of a unique structure. In one of the possible embodiments of the procedure a Prothrombin Time (PT) reagent is prepared. Another possible embodiment of the procedure is the preparation of an activated partial thromboplastin time (APTT) reagent.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: November 29, 2016
    Assignee: Diagon Ltd.
    Inventors: Jozsef Antal, Zoltan Vajda, Zsuzsanna Takatsy, Beata Nagy, Agnes Jakab, Laslo Jakab
  • Patent number: 9492377
    Abstract: The present invention relates to an effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections.
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: November 15, 2016
    Assignee: PROBIOTICAL S.P.A.
    Inventors: Giovanni Mogna, Gian Paolo Strozzi, Luca Mogna
  • Patent number: 9476872
    Abstract: A novel convenient method for evaluating the function of a phagocyte is provided. The method assays sCD14-ST, which is a humoral factor specifically produced in phagocytosis by the phagocyte and which is stable enough for use in an assay. Also provided is a method for detecting diseases associated with the phagocytosis by the phagocyte.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: October 25, 2016
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD
    Inventor: Katsuki Naito
  • Patent number: 9464274
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: October 11, 2016
    Assignee: Anthrogenesis Corporation
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • Patent number: 9439849
    Abstract: Provided is a composition for preventing or alleviating skin wrinkles containing honeybush (Cyclopia intermedia) extract, a fraction thereof, or a fermented honeybush as an active ingredient. More particularly, the honeybush extract or fermented honeybush of the claimed subject matter can reduce the length and depth of skin wrinkles caused by UV irradiation and reduce the thickness of the epidermal layer, in addition to suppress collagen tissue breakdown reactions, indicating it is excellent in alleviating skin wrinkles, so that it can be effectively used as an active ingredient of a composition for preventing or alleviating skin wrinkles.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: September 13, 2016
    Assignee: KOREA INSTITUTE OF ORIENTAL MEDICINE
    Inventors: Sungwook Chae, Hwa-Jung Choi, Jae-Hyoung Song, Goya Choi, Mi Young Lee
  • Patent number: 9421228
    Abstract: A method of treating a disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting a non-syngeneic cell or tissue graft to the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of cells comprising non-graft versus host (GVHD) inducing anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation, and further wherein the cells are either: (i) non-syngeneic with both the subject and the graft; or (ii) non-syngeneic with the graft and syngeneic with the subject, thereby treating the subject.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: August 23, 2016
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Assaf Lask, Eran Ophir, Noga Or-Geva, Adva Cohen, Ran Afik, Esther Bachar-Lustig, Yaki Eidelstein
  • Patent number: 9410120
    Abstract: Provided is a composition for embryo culture, which contains a constitution suitable for embryo culture. Provided is a composition for embryo culture, which contains (a) a constitution shown in Table A below. TABLE A Components mM L-Alanine 0.297 ± 0.089 L-Asparagine 0.015 ± 0.005 L-Aspartic acid 0.120 ± 0.036 L-Glutamic acid 0.550 ± 0.165 Glycine 0.979 ± 0.294 L(?)-Proline 0.105 ± 0.032 L-Serine 0.176 ± 0.053 L(+)-Arginine 0.108 ± 0.032 L(?)-Cystine 0.048 ± 0.014 L-Histidine 0.053 ± 0.016 L(+)-Isoleucine 0.036 ± 0.011 L-Leucine 0.081 ± 0.024 L(+)-Lysine 0.176 ± 0.053 L-Methionine 0.022 ± 0.007 L(?)-Phenylalanine 0.045 ± 0.013 L(?)-Threonine 0.109 ± 0.033 L-Tryptophan 0.018 ± 0.005 L-Tyrosine 0.048 ± 0.014 L-Valine 0.108 ± 0.032 L-Glutamine or 0.398 ± 0.119 glutamine derivative Taurine 1.412 ± 0.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: August 9, 2016
    Assignee: FUSO PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Tatsuma Yao, Yuta Asayama, Akio Matsuhisa
  • Patent number: 9410123
    Abstract: Methods of generating and expanding human hemangio-colony forming cells and non-engrafting hemangio cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells, non-engrafting hemangio cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Human non-engrafting hemangio cells are a novel progenitor cell population that is related to but distinct from the hemangioblast and human hemangio-colony forming cells. The invention also provides compositions, preparations, and solutions comprising hemangio-colony forming cells, non-engrafting hemangio cells or cells differentiated therefrom.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: August 9, 2016
    Assignee: Ocata Therapeutics, Inc.
    Inventors: Robert Lanza, Shi-Jiang Lu